O	O	O	0	5	Novel	Novel	B-NP	JJ	O	2	NMOD	O
O	O	O	6	15	therapies	therapy	I-NP	NNS	O	0	ROOT	O
O	O	O	16	19	for	for	B-PP	IN	O	2	NMOD	O
O	O	O	20	32	inflammatory	inflammatory	B-NP	JJ	O	6	NMOD	O
O	O	O	33	38	bowel	bowel	I-NP	NN	O	6	NMOD	O
O	O	O	39	46	disease	disease	I-NP	NN	O	3	PMOD	O
O	O	O	46	47	.	.	O	.	O	2	P	O

O	O	O	49	56	Looking	Look	B-VP	VBG	O	15	VMOD	O
O	O	O	57	61	back	back	B-ADVP	RB	O	1	VMOD	O
O	O	O	62	64	at	at	B-PP	IN	O	1	VMOD	O
O	O	O	65	74	successes	success	B-NP	NNS	O	6	NMOD	O
O	O	O	75	78	and	and	I-NP	CC	O	6	NMOD	O
O	O	O	79	87	failures	failure	I-NP	NNS	O	3	PMOD	O
O	O	O	88	90	in	in	B-PP	IN	O	6	NMOD	O
O	O	O	91	96	newer	new	B-NP	JJR	O	9	NMOD	O
O	O	O	97	107	approaches	approach	I-NP	NNS	O	7	PMOD	O
O	O	O	108	110	to	to	B-PP	TO	O	9	NMOD	O
O	O	O	111	119	treating	treat	B-VP	VBG	O	10	PMOD	O
O	O	O	120	123	IBD	IBD	B-NP	NN	O	11	OBJ	O
O	O	O	123	124	,	,	O	,	O	15	P	O
O	O	O	125	127	it	it	B-NP	PRP	O	15	SUB	O
O	O	O	128	130	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	131	139	tempting	tempting	B-ADJP	JJ	O	18	AMOD	O
O	O	O	139	140	-	-	O	HYPH	O	18	P	O
O	O	O	140	141	-	-	O	HYPH	O	15	P	O
O	O	O	141	149	although	although	B-SBAR	IN	O	15	VMOD	O
O	O	O	150	155	still	still	B-ADVP	RB	O	21	AMOD	O
O	O	O	156	165	difficult	difficult	B-ADJP	JJ	O	19	SBAR	O
O	O	O	165	166	-	-	O	HYPH	O	21	P	O
O	O	O	166	167	-	-	O	HYPH	O	21	P	O
O	O	O	167	169	to	to	B-VP	TO	O	25	VMOD	O
O	O	O	170	174	draw	draw	I-VP	VB	O	21	VMOD	O
O	O	O	175	186	conclusions	conclusion	B-NP	NNS	O	25	OBJ	O
O	O	O	187	192	about	about	B-PP	IN	O	26	NMOD	O
O	O	O	193	205	pathogenesis	pathogenesis	B-NP	NN	O	27	PMOD	O
O	O	O	205	206	.	.	O	.	O	15	P	O

O	O	O	207	211	When	When	B-ADVP	WRB	O	4	VMOD	O
O	O	O	212	213	a	a	B-NP	DT	O	3	NMOD	O
O	O	O	214	221	therapy	therapy	I-NP	NN	O	4	SUB	O
O	O	O	222	228	proves	prove	B-VP	VBZ	O	0	ROOT	O
O	O	O	229	238	effective	effective	B-ADJP	JJ	O	4	PRD	O
O	O	O	238	239	,	,	O	,	O	4	P	O
O	O	O	240	242	do	do	B-VP	VBP	O	4	DEP	O
O	O	O	243	253	clinicians	clinician	B-NP	NNS	O	7	SUB	O
O	O	O	254	259	truly	truly	B-ADVP	RB	O	7	VMOD	O
O	O	O	260	264	know	know	B-VP	VBP	O	7	VMOD	O
O	O	O	265	268	how	how	B-ADVP	WRB	O	10	VMOD	O
O	O	O	269	271	it	it	B-NP	PRP	O	13	SUB	O
O	O	O	272	277	works	work	B-VP	VBZ	O	11	SBAR	O
O	O	O	277	278	?	?	O	.	O	4	P	O

O	O	O	279	283	Even	Even	B-ADVP	RB	O	14	VMOD	O
O	O	O	284	288	with	with	B-PP	IN	O	1	PMOD	O
O	O	O	289	290	a	a	B-NP	DT	O	4	NMOD	O
O	O	O	291	298	therapy	therapy	I-NP	NN	O	2	PMOD	O
O	O	O	299	301	as	as	B-PP	IN	O	6	AMOD	O
O	O	O	302	310	specific	specific	B-ADJP	JJ	O	4	NMOD	O
O	O	O	311	313	as	as	B-PP	IN	O	6	AMOD	O
O	O	O	314	318	anti	anti	B-NP	AFX	O	11	NMOD	O
O	O	O	318	319	-	-	I-NP	HYPH	B-protein	11	NMOD	B-protein
O	O	O	319	322	TNF	TNF	I-NP	NN	I-protein	11	NMOD	I-protein
O	O	O	323	331	antibody	antibody	I-NP	NN	I-protein	7	PMOD	I-protein
O	O	O	331	332	,	,	O	,	O	14	P	O
O	O	O	333	335	it	it	B-NP	PRP	O	14	SUB	O
O	O	O	336	338	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	339	342	not	not	O	RB	O	14	VMOD	O
O	O	O	343	348	clear	clear	B-ADJP	JJ	O	14	PRD	O
O	O	O	349	351	if	if	B-SBAR	IN	O	14	VMOD	O
O	O	O	352	355	the	the	B-NP	DT	O	19	NMOD	O
O	O	O	356	363	benefit	benefit	I-NP	NN	O	20	SUB	O
O	O	O	364	366	is	be	B-VP	VBZ	O	17	SBAR	O
O	O	O	367	379	attributable	attributable	B-ADJP	JJ	O	20	PRD	O
O	O	O	380	382	to	to	B-PP	TO	O	21	AMOD	O
O	O	O	383	389	simple	simple	B-NP	JJ	O	22	PMOD	O
O	O	O	390	397	binding	binding	I-NP	NN	O	23	NMOD	O
O	O	O	398	401	and	and	I-NP	CC	O	23	NMOD	O
O	O	O	402	411	clearance	clearance	I-NP	NN	O	23	NMOD	O
O	O	O	412	414	of	of	B-PP	IN	O	23	NMOD	O
T1	B-Protein	B-Protein	415	418	TNF	TNF	B-NP	NN	B-protein	30	NMOD	B-protein
T1	I-Protein	I-Protein	418	419	-	-	O	HYPH	O	30	P	O
T1	I-Protein	I-Protein	419	424	alpha	alpha	B-NP	SYM	O	27	PMOD	O
O	O	O	425	427	or	or	B-PP	CC	O	22	PMOD	O
O	O	O	428	430	to	to	B-PP	TO	O	22	PMOD	O
O	O	O	431	438	binding	binding	B-NP	NN	O	40	NMOD	O
O	O	O	439	441	on	on	B-PP	IN	O	33	NMOD	O
O	O	O	442	445	the	the	B-NP	DT	O	37	NMOD	O
O	O	O	446	450	cell	cell	I-NP	NN	O	37	NMOD	O
O	O	O	451	458	surface	surface	I-NP	NN	O	34	PMOD	O
O	O	O	459	462	and	and	O	CC	O	40	NMOD	O
O	O	O	463	473	subsequent	subsequent	B-NP	JJ	O	40	NMOD	O
O	O	O	474	482	deletion	deletion	I-NP	NN	O	32	PMOD	O
O	O	O	483	485	of	of	B-PP	IN	O	40	NMOD	O
O	O	O	486	489	the	the	B-NP	DT	O	44	NMOD	O
O	O	O	490	499	activated	activate	I-NP	VBN	B-cell_type	44	NMOD	B-cell_type
O	O	O	500	510	macrophage	macrophage	I-NP	NN	I-cell_type	41	PMOD	I-cell_type
O	O	O	510	511	.	.	O	.	O	14	P	O

O	O	O	512	516	When	When	B-ADVP	WRB	O	14	VMOD	O
O	O	O	517	518	a	a	B-NP	DT	O	3	NMOD	O
O	O	O	519	523	drug	drug	I-NP	NN	O	4	SUB	O
O	O	O	524	531	appears	appear	B-VP	VBZ	O	1	SBAR	O
O	O	O	532	534	to	to	I-VP	TO	O	6	VMOD	O
O	O	O	535	537	be	be	I-VP	VB	O	4	PRD	O
O	O	O	538	542	less	less	B-ADJP	RBR	O	8	AMOD	O
O	O	O	543	552	effective	effective	I-ADJP	JJ	O	6	PRD	O
O	O	O	553	557	than	than	B-PP	IN	O	8	AMOD	O
O	O	O	558	569	preclinical	preclinical	B-NP	JJ	O	11	NMOD	O
O	O	O	570	576	models	model	I-NP	NNS	O	12	SUB	O
O	O	O	577	584	suggest	suggest	B-VP	VBP	O	9	SBAR	O
O	O	O	584	585	,	,	O	,	O	14	P	O
O	O	O	586	589	can	can	B-VP	MD	O	0	ROOT	O
O	O	O	590	598	failures	failure	B-NP	NNS	O	14	SUB	O
O	O	O	599	601	in	in	B-PP	IN	O	15	NMOD	O
O	O	O	602	615	effectiveness	effectiveness	B-NP	NN	O	16	PMOD	O
O	O	O	616	620	from	from	B-PP	IN	O	17	NMOD	O
O	O	O	621	629	delivery	delivery	B-NP	NN	O	21	NMOD	O
O	O	O	630	632	or	or	I-NP	CC	O	21	NMOD	O
O	O	O	633	639	dosing	dosing	I-NP	NN	O	18	PMOD	O
O	O	O	640	642	be	be	B-VP	VB	O	14	VMOD	O
O	O	O	643	657	differentiated	differentiate	I-VP	VBN	O	22	VC	O
O	O	O	657	658	?	?	O	.	O	14	P	O

O	O	O	659	662	The	The	B-NP	DT	O	3	NMOD	O
O	O	O	663	676	disappointing	disappointing	I-NP	JJ	O	3	NMOD	O
O	O	O	677	684	results	result	I-NP	NNS	O	0	ROOT	O
O	O	O	685	687	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	688	696	clinical	clinical	B-NP	JJ	O	6	NMOD	O
O	O	O	697	703	trials	trial	I-NP	NNS	O	4	PMOD	O
O	O	O	704	708	with	with	B-PP	IN	O	6	NMOD	O
T2	B-Protein	B-Protein	709	711	IL	IL	B-NP	NN	B-protein	9	NMOD	B-protein
T2	I-Protein	I-Protein	711	712	-	-	B-NP	HYPH	I-protein	7	PMOD	I-protein
T2	I-Protein	I-Protein	712	714	10	10	I-NP	CD	I-protein	9	NMOD	I-protein
O	O	O	714	715	-	-	O	HYPH	O	9	P	O
O	O	O	715	716	-	-	O	HYPH	O	9	P	O
O	O	O	716	718	so	so	B-ADVP	RB	O	9	NMOD	O
O	O	O	719	721	at	at	B-PP	IN	O	3	NMOD	O
O	O	O	722	726	odds	odd	B-NP	NNS	O	14	PMOD	O
O	O	O	727	731	with	with	B-PP	IN	O	15	NMOD	O
O	O	O	732	735	the	the	B-NP	DT	O	18	NMOD	O
O	O	O	736	746	prediction	prediction	I-NP	NN	O	16	PMOD	O
O	O	O	747	749	of	of	B-PP	IN	O	18	NMOD	O
O	O	O	750	757	benefit	benefit	B-NP	NN	O	19	PMOD	O
O	O	O	758	762	from	from	B-PP	IN	O	20	NMOD	O
O	O	O	763	769	animal	animal	B-NP	NN	O	23	NMOD	O
O	O	O	770	776	models	model	I-NP	NNS	O	21	PMOD	O
O	O	O	776	777	-	-	O	:	O	3	P	O
O	O	O	777	778	-	-	B-NP	HYPH	O	3	P	O
O	O	O	778	783	bring	bring	B-VP	VBG	O	3	NMOD	O
O	O	O	784	788	into	into	B-PP	IN	O	26	VMOD	O
O	O	O	789	797	question	question	B-NP	NN	O	27	PMOD	O
O	O	O	798	801	the	the	B-NP	DT	O	30	NMOD	O
O	O	O	802	810	validity	validity	I-NP	NN	O	38	NMOD	O
O	O	O	811	813	of	of	B-PP	IN	O	30	NMOD	O
O	O	O	814	819	those	those	B-NP	DT	O	33	NMOD	O
O	O	O	820	826	models	model	I-NP	NNS	O	31	PMOD	O
O	O	O	827	829	as	as	B-CONJP	RB	O	38	NMOD	O
O	O	O	830	834	well	well	I-CONJP	RB	O	34	DEP	O
O	O	O	835	837	as	as	I-CONJP	IN	O	34	DEP	O
O	O	O	838	841	the	the	B-NP	DT	O	38	NMOD	O
O	O	O	842	851	soundness	soundness	I-NP	NN	O	26	OBJ	O
O	O	O	852	854	of	of	B-PP	IN	O	38	NMOD	O
O	O	O	855	861	design	design	B-NP	NN	O	39	PMOD	O
O	O	O	862	864	of	of	B-PP	IN	O	40	NMOD	O
O	O	O	865	868	the	the	B-NP	DT	O	44	NMOD	O
O	O	O	869	877	clinical	clinical	I-NP	JJ	O	44	NMOD	O
O	O	O	878	884	trials	trial	I-NP	NNS	O	41	PMOD	O
O	O	O	885	887	on	on	B-PP	IN	O	44	NMOD	O
O	O	O	888	893	which	which	B-NP	WDT	O	45	PMOD	O
O	O	O	894	902	efficacy	efficacy	B-NP	NN	O	52	SUB	O
O	O	O	903	905	of	of	B-PP	IN	O	47	NMOD	O
T3	B-Protein	B-Protein	906	908	IL	IL	B-NP	NN	B-protein	50	NMOD	B-protein
T3	I-Protein	I-Protein	908	909	-	-	B-NP	HYPH	I-protein	48	PMOD	I-protein
T3	I-Protein	I-Protein	909	911	10	10	I-NP	CD	I-protein	50	NMOD	I-protein
O	O	O	912	914	is	be	B-VP	VBZ	O	45	SBAR	O
O	O	O	915	921	judged	judge	I-VP	VBN	O	52	VC	O
O	O	O	921	922	.	.	O	.	O	3	P	O

O	O	O	923	926	The	The	B-NP	DT	O	2	NMOD	O
O	O	O	927	938	variability	variability	I-NP	NN	O	12	SUB	O
O	O	O	939	941	of	of	B-PP	IN	O	2	NMOD	O
O	O	O	942	950	response	response	B-NP	NN	O	3	PMOD	O
O	O	O	951	955	even	even	B-ADVP	RB	O	12	VMOD	O
O	O	O	956	958	to	to	B-PP	TO	O	5	PMOD	O
O	O	O	959	962	the	the	B-NP	DT	O	9	AMOD	O
O	O	O	963	967	most	most	I-NP	RBS	O	9	AMOD	O
O	O	O	968	976	narrowly	narrowly	I-NP	RB	O	11	NMOD	O
O	O	O	977	985	targeted	target	I-NP	VBN	O	9	AMOD	O
O	O	O	986	992	agents	agent	I-NP	NNS	O	6	PMOD	O
O	O	O	993	1001	suggests	suggest	B-VP	VBZ	O	0	ROOT	O
O	O	O	1002	1006	that	that	B-SBAR	IN	O	12	VMOD	O
O	O	O	1007	1012	these	these	B-NP	DT	O	15	NMOD	O
O	O	O	1013	1021	diseases	disease	I-NP	NNS	O	16	SUB	O
O	O	O	1022	1025	are	be	B-VP	VBP	O	13	SBAR	O
O	O	O	1026	1029	far	far	B-ADJP	RB	O	16	PRD	O
O	O	O	1030	1034	more	more	I-ADJP	RBR	O	17	AMOD	O
O	O	O	1035	1048	heterogeneous	heterogeneous	I-ADJP	JJ	O	17	AMOD	O
O	O	O	1049	1051	in	in	B-PP	IN	O	17	AMOD	O
O	O	O	1052	1058	humans	human	B-NP	NNS	O	20	PMOD	O
O	O	O	1059	1063	than	than	B-PP	IN	O	17	AMOD	O
O	O	O	1064	1066	in	in	B-PP	IN	O	22	PMOD	O
O	O	O	1067	1072	their	their	B-NP	PRP$	O	26	NMOD	O
O	O	O	1073	1079	murine	murine	I-NP	JJ	B-protein	26	NMOD	B-protein
O	O	O	1080	1092	counterparts	counterpart	I-NP	NNS	I-protein	23	PMOD	I-protein
O	O	O	1092	1093	.	.	O	.	O	12	P	O

O	O	O	1094	1104	Clinicians	Clinician	B-NP	NNS	O	2	SUB	O
O	O	O	1105	1108	are	be	B-VP	VBP	O	15	VMOD	O
O	O	O	1109	1113	only	only	I-VP	RB	O	2	VMOD	O
O	O	O	1114	1118	just	just	I-VP	RB	O	2	VMOD	O
O	O	O	1119	1128	beginning	begin	I-VP	VBG	O	2	VC	O
O	O	O	1129	1131	to	to	I-VP	TO	O	7	VMOD	O
O	O	O	1132	1141	recognize	recognize	I-VP	VB	O	5	VMOD	O
O	O	O	1142	1153	subclinical	subclinical	B-NP	JJ	O	9	NMOD	O
O	O	O	1154	1161	markers	marker	I-NP	NNS	O	7	OBJ	O
O	O	O	1162	1164	of	of	B-PP	IN	O	9	NMOD	O
O	O	O	1165	1173	response	response	B-NP	NN	O	10	PMOD	O
O	O	O	1173	1174	,	,	O	,	O	15	P	O
O	O	O	1175	1178	and	and	O	CC	O	15	VMOD	O
O	O	O	1179	1181	it	it	B-NP	PRP	O	15	SUB	O
O	O	O	1182	1185	may	may	B-VP	MD	O	0	ROOT	O
O	O	O	1186	1190	soon	soon	I-VP	RB	O	15	VMOD	O
O	O	O	1191	1193	be	be	I-VP	VB	O	15	VC	O
O	O	O	1194	1202	possible	possible	B-ADJP	JJ	O	17	PRD	O
O	O	O	1203	1205	to	to	B-VP	TO	O	20	VMOD	O
O	O	O	1206	1213	predict	predict	I-VP	VB	O	17	VMOD	O
O	O	O	1214	1222	response	response	B-NP	NN	O	20	OBJ	O
O	O	O	1223	1225	on	on	B-PP	IN	O	21	NMOD	O
O	O	O	1226	1229	the	the	B-NP	DT	O	24	NMOD	O
O	O	O	1230	1235	basis	basis	I-NP	NN	O	22	PMOD	O
O	O	O	1236	1238	of	of	B-PP	IN	O	24	NMOD	O
O	O	O	1239	1246	genetic	genetic	B-NP	JJ	O	27	NMOD	O
O	O	O	1247	1258	composition	composition	I-NP	NN	O	25	PMOD	O
O	O	O	1258	1259	.	.	O	.	O	15	P	O

O	O	O	1260	1263	For	For	B-PP	IN	O	11	VMOD	O
O	O	O	1264	1267	the	the	B-NP	DT	O	3	NMOD	O
O	O	O	1268	1274	moment	moment	I-NP	NN	O	1	PMOD	O
O	O	O	1274	1275	,	,	O	,	O	11	P	O
O	O	O	1276	1283	however	however	B-ADVP	RB	O	11	VMOD	O
O	O	O	1283	1284	,	,	O	,	O	11	P	O
O	O	O	1285	1288	the	the	B-NP	DT	O	8	NMOD	O
O	O	O	1289	1294	field	field	I-NP	NN	O	11	SUB	O
O	O	O	1295	1297	of	of	B-PP	IN	O	8	NMOD	O
O	O	O	1298	1314	pharmacogenetics	pharmacogenetic	B-NP	NNS	O	9	PMOD	O
O	O	O	1315	1317	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	1318	1327	embryonic	embryonic	B-ADJP	JJ	O	11	PRD	O
O	O	O	1327	1328	.	.	O	.	O	11	P	O

O	O	O	1329	1339	Challenges	Challenge	B-NP	NNS	O	7	SUB	O
O	O	O	1340	1342	in	in	B-PP	IN	O	1	NMOD	O
O	O	O	1343	1353	developing	develop	B-VP	VBG	O	2	PMOD	O
O	O	O	1354	1357	new	new	B-NP	JJ	O	6	NMOD	O
O	O	O	1358	1369	therapeutic	therapeutic	I-NP	JJ	O	6	NMOD	O
O	O	O	1370	1380	strategies	strategy	I-NP	NNS	O	3	OBJ	O
O	O	O	1381	1388	include	include	B-VP	VBP	O	0	ROOT	O
O	O	O	1389	1392	not	not	B-CONJP	RB	O	16	VMOD	O
O	O	O	1393	1397	only	only	I-CONJP	RB	O	16	VMOD	O
O	O	O	1398	1409	identifying	identify	B-VP	VBG	O	16	VMOD	O
O	O	O	1410	1415	novel	novel	B-NP	JJ	O	12	NMOD	O
O	O	O	1416	1422	agents	agent	I-NP	NNS	O	10	OBJ	O
O	O	O	1422	1423	,	,	O	,	O	16	P	O
O	O	O	1424	1427	but	but	O	CC	O	16	VMOD	O
O	O	O	1428	1432	also	also	B-ADVP	RB	O	16	VMOD	O
O	O	O	1433	1442	improving	improve	B-VP	VBG	O	7	VMOD	O
O	O	O	1443	1446	the	the	B-NP	DT	O	18	NMOD	O
O	O	O	1447	1458	definitions	definition	I-NP	NNS	O	16	OBJ	O
O	O	O	1459	1461	of	of	B-PP	IN	O	18	NMOD	O
O	O	O	1462	1470	clinical	clinical	B-NP	JJ	O	21	NMOD	O
O	O	O	1471	1480	endpoints	endpoint	I-NP	NNS	O	19	PMOD	O
O	O	O	1481	1484	and	and	O	CC	O	16	VMOD	O
O	O	O	1485	1493	defining	define	B-VP	VBG	O	16	VMOD	O
O	O	O	1494	1502	efficacy	efficacy	B-NP	NN	O	23	OBJ	O
O	O	O	1503	1505	at	at	B-PP	IN	O	24	NMOD	O
O	O	O	1506	1509	the	the	B-NP	DT	O	28	NMOD	O
O	O	O	1510	1518	biologic	biologic	I-NP	JJ	O	28	NMOD	O
O	O	O	1519	1524	level	level	I-NP	NN	O	25	PMOD	O
O	O	O	1524	1525	.	.	O	.	O	7	P	O

O	O	O	1526	1530	Only	Only	B-ADVP	RB	O	8	VMOD	O
O	O	O	1531	1538	through	through	B-PP	IN	O	1	PMOD	O
O	O	O	1539	1549	considered	consider	B-NP	VBN	O	4	NMOD	O
O	O	O	1550	1560	evaluation	evaluation	I-NP	NN	O	2	PMOD	O
O	O	O	1561	1563	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	1564	1572	clinical	clinical	B-NP	JJ	O	7	NMOD	O
O	O	O	1573	1581	evidence	evidence	I-NP	NN	O	5	PMOD	O
O	O	O	1582	1585	may	may	B-VP	MD	O	0	ROOT	O
O	O	O	1586	1596	clinicians	clinician	B-NP	NNS	O	8	SUB	O
O	O	O	1597	1606	determine	determine	B-VP	VB	O	8	VC	O
O	O	O	1607	1612	which	which	B-NP	WDT	O	17	DEP	O
O	O	O	1613	1622	therapies	therapy	I-NP	NNS	O	11	NMOD	O
O	O	O	1623	1629	should	should	B-VP	MD	O	11	SBAR	O
O	O	O	1630	1636	remain	remain	I-VP	VB	O	13	VC	O
O	O	O	1637	1646	novelties	novelty	B-NP	NNS	O	14	PRD	O
O	O	O	1647	1650	and	and	O	CC	O	17	DEP	O
O	O	O	1651	1656	which	which	B-NP	WDT	O	10	VMOD	O
O	O	O	1657	1663	should	should	B-VP	MD	O	17	SBAR	O
O	O	O	1664	1670	become	become	I-VP	VB	O	18	VC	O
O	O	O	1671	1673	an	an	B-NP	DT	O	22	NMOD	O
O	O	O	1674	1682	accepted	accept	I-NP	VBN	O	22	NMOD	O
O	O	O	1683	1687	part	part	I-NP	NN	O	19	PRD	O
O	O	O	1688	1690	of	of	B-PP	IN	O	22	NMOD	O
O	O	O	1691	1694	the	the	B-NP	DT	O	25	NMOD	O
O	O	O	1695	1708	armamentarium	armamentarium	I-NP	NN	O	23	PMOD	O
O	O	O	1708	1709	.	.	O	.	O	8	P	O
